Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | OXTR | P30559 | 3/20 | 0.38 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 9/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 9/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | CFTR | P13569 | 1/20 | 0.31 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4943389 | 1.00 | MMP1 (0.38) | MMP1OXTRAVPR1AHCRTR1HCRTR2 | |
| SCHEMBL5736023 | 1.00 | MMP1 (0.38) | MMP1OXTRAVPR1AHCRTR1HCRTR2 | |
| SCHEMBL4943396 | 1.00 | MMP1 (0.38) | MMP1OXTRAVPR1AHCRTR1HCRTR2 | |
| SCHEMBL4941478 | 0.79 | OXTR (0.43) | MMP1OXTRAVPR1ALMNADPP4 | |
| SCHEMBL4941472 | 0.79 | OXTR (0.43) | MMP1OXTRAVPR1ALMNADPP4 | |
| SCHEMBL4944080 | 0.78 | RORC (0.50) | HCRTR1LMNAPOLBMEN1ALDH1A1 | |
| SCHEMBL4944078 | 0.78 | RORC (0.50) | HCRTR1LMNAPOLBMEN1ALDH1A1 | |
| SCHEMBL4936492 | 0.73 | ALDH1A1 (0.44) | MMP1OXTRAVPR1AALDH1A1KMT2A | |
| SCHEMBL4936495 | 0.73 | ALDH1A1 (0.44) | MMP1OXTRAVPR1AALDH1A1KMT2A | |
| SCHEMBL4943245 | 0.73 | OXTR (0.45) | OXTRAVPR1ALMNAGLAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268418-B1 | PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS | APPLIED RESEARCH SYSTEMS (AN) | 2006-06-14 | — | — | EP | disclosed |
| US-7018988-B2 | Pharmaceutically active pyrrolidine derivatives as Bax inhibitors | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-03-28 | — | — | US | disclosed |
| US-20030171309-A1 | Pharmaceutically active pyrrolidine derivatives as bax inhibitors | MERCK SERONO SA (CH) | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171309-A1 | Pharmaceutically active pyrrolidine derivatives as bax inhibitors | SUCNR1, PYCR1, GLS | MMP1 4354/4885OXTR 189/4885AVPR1A 1456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.